Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073133 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL9270945 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL3083781 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL9270948 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL5372580 | 0.88 | ALDH1A1 (0.59) | ALDH1A1ALOX15PTPN1BTN3A1 | |
| SCHEMBL9013663 | 0.88 | ALDH1A1 (0.59) | ALDH1A1ALOX15PTPN1BTN3A1 | |
| SCHEMBL11410939 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL806725 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1301763 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1301765 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204271-A1 | ANTI-SARS-COV-2 AGENT AND COMPOUND USE | 国立大学法人 鹿児島大学 | 2023-10-26 | — | — | WO | disclosed |
| EP-1797953-B1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1797953-A1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1358144-B1 | EPOTHILONE SYNTHESIS COMPONENTS I: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE AND EPOTHILONE DERIVATIVES | R & D BIOPHARMACEUTICALS (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-6867333-B2 | EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | R & D BIOPHARMACEUTICALS GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1358144-A1 | EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES | Morphochem AG (DE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002032844-A2 | EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2002-04-25 | — | — | WO | disclosed |
| US-5354874-A | Intermediates for Sarcophytol A; antitumor, anticarcinogenic agent | MITSUBISHI KASEI CORPORATION (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5324869-A | Chemical intermediates for sarcophytol a | MITSUBISHI KASEI CORPORATION (JP) | 1994-06-28 | — | — | US | disclosed |
| US-5304661-A | Chemical intermediate for sarcophytol a | MITSUBISHI KASEI CORPORATION (JP) | 1994-04-19 | — | — | US | disclosed |
| US-5245085-A | Chemical intermediates for sarcophytol A, an anticancer and antitumor agent | MITSUBISHI KASEI CORPORATION (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0455826-A1 | SUBSTITUTED OPEN-CHAIN TERPENE COMPOUND | Mitsubishi Chemical Corporation (JP) | 1991-11-13 | — | — | EP | disclosed |
| US-4199519-A | TREATMENT OF PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1980-04-22 | — | — | US | disclosed |
| US-4151357-A | FOR PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | AOC2, AOX1, CAT | ALDH1A1 36/4885ALOX15 312/4885FNTA 3062/4885 |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | COASY, ACOX1, FDFT1 | ALDH1A1 1538/4885ALOX15 89/4885FNTA 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.